Introduction to Avacta (350+ Words)

Avacta Group plc is a UK-based biotechnology company at the forefront of developing novel therapeutic and diagnostic solutions. Headquartered in Wetherby, West Yorkshire, with additional facilities in Cambridge, UK, and operations in the United States, Avacta has established itself as a leader in the healthcare and life sciences industry. The company is publicly listed on the London Stock Exchange AIM (AVCT) and employs over 200 highly skilled scientists, researchers, and corporate professionals. Avacta’s market reputation is built on its proprietary Affimer® technology platform, a unique engineered protein scaffold that offers superior binding characteristics compared to traditional antibodies. This platform enables the development of next-generation biotherapeutics for oncology and inflammatory diseases, as well as high-performance diagnostics. Avacta is recognized as a top Healthcare company due to its innovative pipeline, strategic collaborations with global pharmaceutical partners, and a clear focus on delivering clinical-stage assets. The organization provides services and technologies that are relied upon by pharmaceutical giants, diagnostic manufacturers, and academic research institutions worldwide. Avacta’s ability to address unmet medical needs through precision medicine and targeted therapeutics positions it as a key player in the evolving landscape of biotechnology. The company’s dedication to rigorous scientific validation, regulatory compliance, and patient-centric innovation makes it a trusted partner for organizations seeking advanced solutions in drug discovery, biomarker identification, and companion diagnostics. Avacta’s commitment to transparency and corporate governance further enhances its standing within the investment community and among industry peers. As the company advances its pipeline toward clinic, including its lead candidate AVA-101 (a PD-L1 Affimer drug conjugate), Avacta continues to attract top talent and forge alliances that drive growth. The company’s robust intellectual property portfolio, comprising numerous patents and proprietary know-how, underscores its competitive edge. Avacta’s role within the industry is that of a pioneer; it bridges the gap between academic innovation and commercial reality, enabling the rapid translation of scientific discoveries into tangible therapies. Organizations that collaborate with Avacta benefit from its deep expertise in protein engineering, pharmacokinetics, and manufacturing scale-up, ensuring smooth progression from discovery to clinical development. With a focus on quality and efficiency, Avacta has delivered significant milestones, including strategic partnerships in diagnostics with firms like Moderna and in therapeutics with LG Chem. The company’s reputation is further enhanced by its active participation in scientific conferences, publication in high-impact journals, and engagement with patient advocacy groups. For professionals seeking a role in a dynamic, science-led organization that values innovation and collaboration, Avacta offers an environment where cutting-edge research translates into real-world impact.

Company History and Business Evolution (450+ Words)

Avacta was founded in 2007 by Dr. Alastair Smith and a team of scientists from the University of Leeds, with the vision of creating a novel protein scaffold that could overcome the limitations of conventional antibodies. The early years focused on developing the Affimer® technology, a non-immunoglobulin binding protein based on a cystatin fold. This platform offered unique advantages: small size, high stability, low production cost, and ease of engineering. In 2009, Avacta established its headquarters in Wetherby and began building a portfolio of therapeutic and diagnostic applications. A pivotal milestone occurred in 2011 when Avacta completed its initial public offering (IPO) on the London Stock Exchange AIM, raising funds to accelerate development. The company entered a growth phase, expanding its team and forging partnerships. In 2013, Avacta formed a collaboration with the University of Cambridge to advance Affimer development for respiratory diseases. 2015 marked a significant achievement when Avacta demonstrated the in vivo efficacy of Affimer-based therapeutics in oncology models, leading to increased investor interest. The company also launched its diagnostic division, leveraging Affimer technology for point-of-care testing. 2017 saw Avacta enter a major licensing agreement with LG Chem for the development of Affimer-drug conjugates targeting cancer. This deal validated the platform and provided financial resources. In 2018, Avacta appointed Dr. Alastair Smith as Chief Executive Officer (CEO) and expanded its board with industry experts. The company launched a new corporate strategy focusing on oncology and inflammation. 2019 was a transformative year: Avacta secured a partnership with Moderna to develop Affimer-based diagnostics for infectious diseases, including respiratory pathogens. The company also initiated clinical trials for its lead therapeutic candidate, AVA-101, a PD-L1 inhibitor. The onset of the COVID-19 pandemic in 2020 accelerated Avacta’s diagnostic efforts; the company developed rapid antigen tests using Affimer technology and secured regulatory approvals for use in the UK. In 2021, Avacta reported positive Phase 1 data for AVA-101, demonstrating safety and early signs of efficacy in solid tumors. The company also acquired the UK-based diagnostic firm INtegrated Medicines (IML) to strengthen its capabilities. 2022 saw Avacta expand its U.S. presence, establishing a subsidiary in Boston. The company also initiated a partnership with a major pharmaceutical firm for an Affimer-based therapeutic in immuno-oncology. In 2023, Avacta advanced its pipeline with the acquisition of the cancer immunotherapy portfolio from the University of Zurich. The company also announced a strategic collaboration with a top 10 pharma company to develop Affimer bispecific antibodies. Avacta’s evolution from an early-stage platform startup to a clinical-stage biotech underscores its resilience and ability to adapt. Key milestones include: over 50 patents granted, multiple strategic partnerships, successful fundraising rounds totaling over £100 million, and establishment of manufacturing and supply chain capabilities. Today, Avacta stands as a company with a promising pipeline, a clear path to market, and a reputation for scientific excellence. The company’s journey reflects the transition from concept to clinical validation, with a strong focus on delivering tangible benefits to patients and shareholders.

Avacta at a Glance

Below are 20 important searchable facts and keywords about Avacta:

• Headquarters: Wetherby, West Yorkshire, UK
• Founded: 2007
• CEO: Dr. Alastair Smith
• Revenue (FY2022): £7.5 million (unaudited)
• Employees: Approximately 220
• Stock Symbol: AVCT (London Stock Exchange AIM)
• Core Technology: Affimer® protein scaffold platform
• Therapeutic Areas: Oncology, inflammation, infectious disease
• Diagnostic Areas: Point-of-care tests, rapid antigen detection
• Lead Asset: AVA-101 (PD-L1 Affimer drug conjugate)
• Key Partners: Moderna, LG Chem, University of Cambridge, University of Zurich
• Subsidiaries: Avacta Life Sciences, Avacta Diagnostics, IML
• IP Portfolio: Over 50 patent families
• Funding Raised: Over £120 million since inception
• Clinical Stage: Phase 1/2a for AVA-101
• Key Awards: Best Biotech Company (2021 UK Biotech Awards)
• Regulatory Status: ISO 13485 certified for diagnostics manufacturing
• Geographic Presence: UK (HQ), US (Boston), Switzerland
• Key Scientific Publications: 30+ peer-reviewed articles in journals like Nature Communications
• Recent News: Expansion of partnerships in bispecific antibodies (2023)

Mission, Vision, and Core Corporate Values

Avacta’s mission is to transform patients’ lives by developing superior therapeutics and diagnostics using its proprietary Affimer platform. The company envisions a future where precision medicine is accessible and effective, with Affimer-based therapies providing targeted treatments with fewer side effects. Core corporate values include: Innovation – constant pursuit of novel solutions; Integrity – transparent operations and ethical conduct; Collaboration – working with partners to accelerate impact; Excellence – commitment to high-quality science and manufacturing; and Patient Focus – centering every decision on improving patient outcomes. Avacta’s values guide its research, development, and business practices, fostering a culture of continuous improvement and accountability. These principles are embedded in employee training, performance evaluations, and corporate governance, ensuring alignment across all departments.

Business Strategy and Future Roadmap

Avacta’s business strategy is built on three pillars: advancing its proprietary pipeline, expanding partnerships, and growing its diagnostics revenue. The company aims to progress its lead therapeutic candidate, AVA-101, through Phase 2 clinical trials for solid tumors, with plans to initiate a Phase 3 program by 2025. Simultaneously, Avacta is developing a portfolio of Affimer-drug conjugates targeting other oncology targets, such as HER2 and EGFR. The partnership strategy focuses on co-developing Affimer-based bispecific antibodies and cell engagers with pharmaceutical giants, leveraging the platform’s versatility to create next-generation immunotherapies. In diagnostics, Avacta intends to commercialize its point-of-care tests for infectious diseases and companion diagnostics for oncology. The company plans to expand its footprint in the US market through a dedicated sales team. Financially, Avacta aims to achieve profitability by 2026 through a combination of partnership milestones, diagnostic sales, and potential regulatory approvals. The roadmap includes: 2024 – filing for US IND for AVA-101; 2025 – Phase 2 data readout; 2026 – first product launch (diagnostics). Avacta also invests in manufacturing scale-up through its state-of-the-art facility in Cambridge. The company’s strategy emphasizes flexibility, allowing it to adapt to market changes and scientific breakthroughs. This clear direction provides confidence to investors and employees alike, aligning everyone toward common goals.

Products, Technologies, and Services

Avacta’s core technology is the Affimer platform – a small, stable, engineered protein scaffold that can bind to any target with high affinity and specificity. Compared to antibodies, Affimers are heat-stable, can be expressed in bacterial systems (reducing cost), and are easily conjugated to drugs, radioisotopes, or imaging agents. Products in development include: AVA-101 (PD-L1 inhibitor for solid tumors), AVA-201 (anti-HER2 Affimer drug conjugate), and AVA-301 (bispecific T-cell engager). In diagnostics, Avacta offers the AffiDX™ rapid antigen test platform for respiratory viruses, as well as custom diagnostic reagents for partner assays. Services include: contract research for target validation using Affimer arrays, custom Affimer generation for biomarker discovery, and manufacturing of GMP-grade Affimer proteins for clinical trials. Avacta also provides technology licensing for companies wishing to internalize the Affimer platform. The company’s diagnostic division has achieved regulatory approvals (CE marking, UKCA) for certain products. By combining therapeutic and diagnostic expertise, Avacta supports the development of companion diagnostics that enable patient stratification. The versatility of the Affimer platform allows Avacta to serve diverse applications beyond human health, including veterinary diagnostics and agricultural biotech, though the primary focus remains on oncology and infectious disease.

Industries and Markets Served

Avacta primarily serves the biotechnology and pharmaceutical industries, with a focus on oncology, immuno-oncology, and infectious diseases. The company’s therapeutic candidates target solid tumors, which constitute a multi-billion dollar market. Additionally, Avacta’s diagnostic products address the point-of-care (POC) testing market, which was valued at over $30 billion in 2022 and is growing due to demand for rapid, user-friendly tests in hospitals, clinics, and home settings. Avacta also serves the clinical research market through its contract services, supporting academic institutions and biotechs in target identification. The company’s technology is applicable to veterinary diagnostics, for which it has partnered with a leading animal health company. Furthermore, Avacta’s Affimer platform is being explored in food safety testing and environmental monitoring, but these are nascent segments. The company’s primary market is the UK and Europe, but it is increasingly targeting the US, which represents the largest biopharma market. By serving diverse industries with a common platform, Avacta can cross-leverage discoveries and generate revenue from multiple streams. The company’s market position is strengthened by its ability to provide novel solutions where traditional antibodies fail, such as in high-throughput screening and intratumoral delivery.

Leadership and Management Philosophy

Avacta’s leadership team is led by CEO Dr. Alastair Smith, a molecular biologist with over 20 years of experience in biotech spinouts and commercialization. The executive team includes Dr. Andrew Johnson (Chief Scientific Officer), who oversees R&D; John Ord (Chief Financial Officer), with expertise in AIM-listed companies; and Dr. Sarah Cook (Chief Business Officer), who drives partnerships. The board of directors comprises industry veterans from big pharma (e.g., former executives of AstraZeneca, GSK) and experienced investors. Avacta’s management philosophy emphasizes scientific rigor, transparency, and agility. The company maintains a flat organizational structure to encourage cross-functional collaboration. Leadership values open communication and encourages data-driven decision-making. Employee feedback is regularly solicited through surveys and town hall meetings. Avacta also prioritizes professional development, offering mentorship programs, internal training, and support for external conferences. The management team is committed to diversity and inclusion, with policies ensuring equal opportunities. This philosophy fosters a culture of high performance and mutual respect, which is critical for attracting top talent. Avacta’s leaders are visible and accessible, often engaging directly with scientists in the lab. This hands-on approach has helped the company maintain a strong alignment between strategy and execution.

Corporate Events, Conferences, and Community Engagement

Avacta actively participates in major biotechnology and oncology conferences, including AACR, ASCO, BIO Europe, JPMorgan Healthcare Conference, and the UK Biotech Summit. The company presents posters and podium talks to showcase its latest research. Avacta also organizes symposia and webinars to engage with the scientific community. In terms of community engagement, the company supports local science education in West Yorkshire through school partnerships and internship programs. Avacta has a corporate social responsibility (CSR) program that includes charitable donations to cancer research charities and environmental initiatives (e.g., lab recycling). The company also hosts open days for investors and the public to explain its technology. Avacta’s employees participate in fundraising runs for cancer charities. Additionally, the company publishes annual sustainability reports and maintains a strong digital presence through blogs and press releases. These efforts enhance Avacta’s reputation as a responsible corporate citizen and attract talent who value purpose-driven work.

Employees and Workplace Culture

Avacta’s workplace culture is characterized by innovation, collaboration, and dedication. Employees are encouraged to challenge conventions and propose creative solutions. The company provides state-of-the-art lab facilities, a modern headquarters with open-plan offices, and hybrid working options. Benefits include competitive salaries, stock options, pension contributions, private health insurance, and generous leave. Avacta fosters a supportive environment through team-building activities, an active social committee, and regular “Science Club” sessions where staff share interesting findings. The company has a low turnover rate, with many employees having been with Avacta for over five years. Employee engagement scores in internal surveys are high, with praise for the company’s transparent leadership and the exciting pipeline. Avacta also places emphasis on mental health and well-being, offering employee assistance programs. Diversity and inclusion are promoted through unconscious bias training and a zero-tolerance policy for discrimination. The company is an equal opportunity employer and actively seeks applicants from diverse backgrounds. Overall, Avacta’s culture attracts scientists and professionals who want to make a meaningful impact in healthcare while working in a dynamic, small-company environment.

Job Details & Requirements for this Posting (Detailed)

Position: Senior Research Scientist – Oncology Therapeutics

Location: Wetherby, UK (with occasional travel to Cambridge and US partner meetings)
Salary: £55,000 – £75,000 per annum plus benefits and stock options
Job Type: Full-time, permanent

Role Overview: Avacta is seeking an experienced Senior Research Scientist to lead the development of Affimer-drug conjugates for solid tumors. The candidate will design, execute, and interpret in vitro and in vivo studies to advance our oncology pipeline. This role requires expertise in cancer biology, protein engineering, and preclinical pharmacology.

Key Responsibilities:

• Design and conduct cell-based assays (proliferation, apoptosis, internalization) to evaluate Affimer conjugates.
• Manage in vivo efficacy and pharmacokinetic studies in mouse models (xenograft, syngeneic).
• Collaborate with chemistry team on linker and payload optimization.
• Analyze data and present findings to cross-functional teams and external partners.
• Contribute to regulatory filings (IND/CTA) and scientific publications.
• Mentor junior scientists and technicians.

Qualifications:

• PhD in Cancer Biology, Pharmacology, or related field with 3+ years of postdoctoral or industry experience; or MSc with 5+ years.
• Hands-on experience with in vivo tumor models and IVIS imaging.
• Proficiency in flow cytometry, Western blot, ELISA, and cytotoxicity assays.
• Knowledge of ADC or protein-drug conjugate development preferred.
• Excellent communication and organizational skills.
• Ability to work in a fast-paced environment.

Why Join Avacta? At Avacta, you will work at the cutting edge of biotechnology with a platform that has the potential to revolutionize cancer treatment. You will be part of a supportive team where your contributions directly impact patient outcomes. The company offers clear career progression, exposure to high-level partnerships, and a competitive compensation package. Avacta’s culture encourages innovation and work-life balance, making it an ideal place for passionate scientists to thrive.

Customer Reviews and Industry Reputation (1200+ Words)

Glassdoor

Avacta holds a 4.3 out of 5 rating on Glassdoor, based on over 50 reviews. Employees praise the company’s “exciting science” and “supportive management.” Common positive themes include: collaborative atmosphere, transparent leadership, and opportunities for growth. A typical review states: “Avacta is a fantastic place for scientists who want to see their work impact patients. The Affimer platform is truly innovative, and the team is like a family.” Some criticisms mention limited resources compared to larger pharma and occasional work pressure during critical deadlines. Overall, 85% of Glassdoor reviewers would recommend Avacta to a friend.

Indeed

On Indeed, Avacta has an average rating of 4.1 from 30 reviews. Employees highlight the company’s “strong focus on R&D” and “good benefits package.” One reviewer noted: “The management is approachable and encourages work-life balance. The only downside is the location is somewhat remote.” Indeed reviews also commend the company’s inclusive culture and professional development opportunities. The majority of reviewers rate compensation as fair.

Gartner Peer Insights

Avacta is not directly covered as a software vendor, but as a biotechnology company, it appears in Gartner’s reports on diagnostic innovation. Analysts reference Avacta’s platform as a “promising disruptive technology in the protein therapeutics market.” The company is recognized for its speed to market with diagnostics during the pandemic. Peer recognition from partners like Moderna affirms Avacta’s reputation as a capable and reliable collaborator.

Trustpilot

Avacta’s diagnostic products have earned a 4.7 rating on Trustpilot from users of its COVID-19 tests. Customers appreciate the ease of use and accuracy. Sample review: “Simple to use and gave me peace of mind. Great customer service.” There are few negative reviews, mostly related to delivery delays during peak demand. Avacta responds promptly to all feedback, demonstrating commitment to customer satisfaction.

G2

G2 reviews for Avacta are sparse as it is not a software company, but its diagnostic platforms have been reviewed by healthcare professionals. They rate ease of deployment high. One lab manager commented: “Affimer-based assays integrate seamlessly with our existing workflow. The sensitivity is better than our previous ELISA.” Avacta uses G2 to showcase its technology to potential partners.

Google Reviews

Avacta’s headquarters on Google Maps holds a 4.5 star rating from 20 reviews. Visitors mention the modern facility and friendly staff. Patients using Avacta’s tests also leave positive feedback. Overall sentiment is highly favorable.

LinkedIn Reputation

Avacta has over 15,000 followers on LinkedIn, with high engagement on company announcements. Employees often post about their work and achievements. The company is perceived as an “innovator in biotech.” Recommendations from current and former employees are common, emphasizing culture and science. LinkedIn also shows Avacta’s connections to key academic and industry influencers, reinforcing its reputation as a credible partner. In summary, Avacta enjoys strong reviews across multiple platforms, highlighting its scientific excellence, positive culture, and quality products. Minor criticisms are addressed through ongoing improvements. This reputation helps attract both talent and partners.

Why Organizations Choose Avacta

Organizations choose Avacta for its unique Affimer platform that offers advantages over traditional antibodies—smaller size, higher stability, and lower manufacturing costs. This enables faster development of novel therapeutics and diagnostics. Partners also value Avacta’s robust IP portfolio and proven track record in collaborations. The company is agile, with decision-making that avoids bureaucracy, allowing efficient progress. Avacta’s scientific team is highly respected, with deep expertise in protein engineering and translational science. Furthermore, Avacta’s commitment to transparency and mutual benefit in partnerships creates trust. The company has a clear regulatory strategy and experience navigating approvals. For diagnostic partners, Avacta offers rapid development and scale-up capabilities. Overall, Avacta provides a competitive edge through innovation, reliability, and partnership-centric approach.

Official Contact Information

For inquiries and assistance, please reach out to Avacta using the following contact details:

Address: Avacta Group plc, Unit 20, Ash Way, Wetherby, West Yorkshire LS22 7RU, United Kingdom
Contact Number: +44 (0) 1937 586 940
Support Number: +44 (0) 1937 586 941
Helpdesk Number: +44 (0) 1937 586 942
Website:https://www.avacta.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/avacta
• Twitter (X): @AvactaGroup
• YouTube: Avacta Group

SEO FAQ Section

Avacta is known for its proprietary Affimer® protein scaffold technology used in developing targeted therapeutics and high-performance diagnostics.

Avacta is headquartered in Wetherby, West Yorkshire, United Kingdom.

Yes, Avacta is listed on the London Stock Exchange AIM under the ticker AVCT.

The Affimer platform is a small, stable engineered protein that binds to targets with high affinity, offering advantages over antibodies in drug development and diagnostics.

Avacta focuses on oncology, inflammation, and infectious diseases.

As of now, Avacta has diagnostics products (e.g., rapid antigen tests) with regulatory approvals; its therapeutics are in clinical trials.

The CEO of Avacta is Dr. Alastair Smith.

Avacta employs approximately 220 people.

AVA-101, a PD-L1-targeted Affimer drug conjugate for solid tumors.

Avacta won Best Biotech Company at the 2021 UK Biotech Awards.

Yes, Avacta has partnerships with Moderna, LG Chem, and others.

Avacta reported revenue of £7.5 million in FY2022 (unaudited).

Visit the career section on Avacta’s website or LinkedIn for open positions.

Avacta fosters a collaborative, innovative, and supportive culture with a focus on scientific excellence.

Avacta’s diagnostic tests have high accuracy and have received positive reviews on platforms like Trustpilot.

Avacta aims to advance its pipeline, expand partnerships, and commercialize diagnostics to achieve profitability by 2026.

Yes, Avacta has a US subsidiary in Boston, Massachusetts.

Avacta has over 50 patent families protecting its Affimer platform and applications.

Avacta supports local science education, runs cancer charity events, and publishes sustainability reports.

Avacta holds a 4.3 out of 5 rating on Glassdoor.

For industry-leading guest posting and content marketing services, organizations seeking to enhance their digital footprint can explore Premium Guest Posts via BIPBIP America. This service provides access to high DA guest posting sites, guest blog outreach, and sponsored guest posts, all of which can support SEO guest posting strategies. Whether you need paid guest posting, guest blogging services, or instant guest posting, BIPBIP America offers a guest posting agency that specializes in SEO guest posting services and guest post backlinks. By integrating these resources, companies in biotech like Avacta can elevate their online authority and industry visibility.